Clinical Trials Browser

Phase 2 × INDUSTRY × Has announcements × Clear all

NCT02365597 2026-04-13

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Phase 2 Active not recruiting

239 enrolled 32 charts 2 FDA

Urothelial Cancer

NCT02864992 2026-04-13

VISION

Phase 2 Active not recruiting

337 enrolled 13 charts 4 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04557098 2026-04-13

MajesTEC-1

Phase 2 Active not recruiting

194 enrolled 2 FDA

Other hematologic neoplasm

Hematologic Neoplasms

NCT04634552 2026-04-13

MonumenTAL-1

Phase 2 Recruiting

510 enrolled 2 FDA

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT04640623 2026-04-13

SunRISe-1

Phase 2 Active not recruiting

220 enrolled 3 FDA

Urinary Bladder Neoplasms

NCT04924075 2026-04-13

MK-6482-015

Phase 2 Recruiting

322 enrolled 3 FDA

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT04482309 2026-04-09

DPT02

Phase 2 Active not recruiting

477 enrolled 2 FDA

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT03962543 2026-04-08

ReNeu

Phase 2 Active not recruiting

114 enrolled 25 charts 3 FDA

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT04589845 2026-04-02

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Phase 2 Active not recruiting

920 enrolled 2 FDA

Other solid neoplasm

Solid Tumors

NCT02360579 2026-03-25

LN-144

Phase 2 Completed

220 enrolled 16 charts 1 FDA

Melanoma

NCT03915951 2026-03-24

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Phase 2 Completed

98 enrolled 18 charts 2 FDA

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT04484142 2026-03-24

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

Phase 2 Completed

137 enrolled 9 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT02601313 2026-03-18

ZUMA-2

Phase 2 Completed

105 enrolled 33 charts 3 FDA

Lymphoma, Mantle-Cell

NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Phase 2 Completed

378 enrolled 15 charts 2 FDA

Uveal Melanoma, Melanoma

NCT03547973 2026-03-16

TROPHY U-01

Phase 2 Recruiting

827 enrolled 2 FDA

Metastatic Urothelial Cancer

NCT04710576 2026-03-16

AGAVE-201

Phase 2 Active not recruiting

241 enrolled 11 charts 3 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT02568267 2026-03-06

STARTRK-2

Phase 2 Active not recruiting

534 enrolled 2 FDA

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT03363373 2026-02-19

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Phase 2 Recruiting

122 enrolled 3 FDA

Neuroblastoma

NCT03332017 2026-02-18

ROSEWOOD

Phase 2 Completed

217 enrolled 23 charts 2 FDA

Lymphoma, Follicular

NCT04711135 2026-02-12

NETTER-P

Phase 2 Active not recruiting

11 enrolled 14 charts 2 FDA

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT02213926 2026-02-10

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Phase 2 Active not recruiting

124 enrolled 10 charts 2 FDA

Lymphoma, Mantle-Cell

NCT04044768 2026-02-06

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

52 enrolled 15 charts 1 FDA

Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT04395677 2026-02-06

A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

Phase 2 Active not recruiting

173 enrolled 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT04744831 2026-01-14

DESTINY-CRC02

Phase 2 Completed

122 enrolled 21 charts 2 FDA

Gastrointestinal

Colorectal Neoplasms

NCT04919811 2026-01-07

TRUST-II

Phase 2 Active not recruiting

217 enrolled 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT03105336 2025-12-23

ZUMA-5

Phase 2 Completed

159 enrolled 27 charts 2 FDA

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT05060016 2025-12-22

DeLLphi-301

Phase 2 Active not recruiting

222 enrolled 2 FDA

Small Cell Lung Carcinoma

NCT04649359 2025-12-02

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Phase 2 Active not recruiting

187 enrolled 14 charts 2 FDA

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04644237 2025-11-21

DESTINY-LUNG02

Phase 2 Completed

152 enrolled 22 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03011372 2025-11-18

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

Phase 2 Completed

47 enrolled 21 charts 2 FDA

Eosinophilia, Myeloproliferative Disorders

NCT02576431 2025-11-12

NAVIGATE

Phase 2 Completed

215 enrolled 5 FDA

BreastDermatologicGastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Salivary Gland Neoplasms, Sarcoma, Thyroid Neoplasms, Colorectal Neoplasms

NCT02060188 2025-11-06

CheckMate142

Phase 2 Completed

385 enrolled 17 charts 4 FDA

GastrointestinalOther solid neoplasm

Microsatellite Unstable Colorectal Cancer

NCT03539536 2025-11-05

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

270 enrolled 3 FDA

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT04245839 2025-11-05

TRANSCEND FL

Phase 2 Active not recruiting

276 enrolled 5 FDA

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT03568461 2025-10-07

ELARA

Phase 2 Completed

98 enrolled 9 charts 2 FDA

Lymphoma, Follicular, Recurrence

NCT02227251 2025-10-01

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 Recruiting

244 enrolled 3 FDA

Lymphoma, Large B-Cell, Diffuse

NCT02628067 2025-09-22

KEYNOTE 158

Phase 2 Active not recruiting

1,609 enrolled 9 FDA

EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

NCT04466891 2025-09-15

HERIZON-BTC-01

Phase 2 Completed

87 enrolled 25 charts 3 FDA

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms

NCT01784068 2025-09-10

ENESTfreedom

Phase 2 Completed

215 enrolled 7 charts 2 FDA

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03525678 2025-09-03

A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

Phase 2 Completed

221 enrolled 61 charts 3 FDA

Multiple Myeloma

NCT01698905 2025-09-02

ENESTop

Phase 2 Completed

163 enrolled 7 charts 2 FDA

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03597295 2025-08-21

A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)

Phase 2 Completed

94 enrolled 18 charts 3 FDA

Gastrointestinal

Squamous Cell Carcinoma of Anal Canal

NCT02924376 2025-08-14

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

Phase 2 Completed

147 enrolled 22 charts 3 FDA

Gastrointestinal

Acrocephalosyndactylia, Cholangiocarcinoma

NCT03599713 2025-08-05

A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)

Phase 2 Completed

107 enrolled 16 charts 2 FDA

Carcinoma, Merkel Cell

NCT03295396 2025-07-28

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

Phase 2 Terminated

73 enrolled 13 charts 3 FDA

Glioma

NCT03248492 2025-06-26

DESTINY-Breast01

Phase 2 Terminated

253 enrolled 21 charts 2 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT02601950 2025-06-22

A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma

Phase 2 Completed

267 enrolled 25 charts 3 FDA

Sarcoma, Sarcoma, Synovial

NCT03505710 2025-05-30

DESTINY-Lung01

Phase 2 Terminated

181 enrolled 17 charts 2 FDA

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03361748 2025-05-23

KarMMa

Phase 2 Completed

149 enrolled 29 charts 1 FDA

Multiple Myeloma, Recurrence

NCT03580655 2025-04-30

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Phase 2 Completed

107 enrolled 2 FDA

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic